Nov 26 (Reuters) - Novo Nordisk A/S NOVOb.CO :
* REG-NOVO NORDISK ANNOUNCES IMPACT FROM VOLUME BASED PROCUREMENT FOR INSULIN IN CHINA
* WILL PROVIDE FINANCIAL OUTLOOK FOR 2022 IN CONNECTION WITH ANNOUNCEMENT OF FULL-YEAR 2021 RESULTS ON 2 FEBRUARY 2022.
* CURRENTLY EXPECTS AN ESTIMATED NEGATIVE IMPACT ON GLOBAL SALES GROWTH OF AROUND 3% IN 2022
* REDUCED PRICES AND REDUCED VOLUMES OF INSULIN SOLD IN CHINA.
* VBP FOR INSULIN IS EXPECTED TO BE IMPLEMENTED DURING FIRST HALF OF 2022
Source text for Eikon: ID:nGNE6sgxcR Further company coverage: NOVOb.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))